Items Tagged ‘aromatase inhibitors’

November 15th, 2016

Aromatase Inhibitor–Associated Joint Pain Tends to Resolve Upon Treatment Completion

By

A class of drugs known as aromatase inhibitors (AI) commonly used in the management of estrogen receptor-positive (ER+) breast cancer are associated with troublesome joint pain. In fact, as many as half of women on AI therapy experience joint pain, and 20% become non-compliant with their AI therapy because of side effects.1 The origin of […]

View full entry

Tags: AI, aromatase inhibitors, Breast Cancer, ER-positive, joint pain, News


June 7th, 2016

Treatment with Aromatase Inhibitors for 10 Years Improves Cancer-Free Survival in Breast Cancer

By

Among postmenopausal women with hormone-positive, early breast cancer, treatment with aromatase inhibitors (AIs) for 10 years significantly improves cancer-free survival, compared to the 5-year standard length of AI treatment.  However, quality of life issues, bone density concerns, and a patient’s risk of a recurrence should be taken into consideration to determine the optimal length of […]

View full entry

Tags: AIs, aromatase inhibitors, Breast Cancer, early-stage, hormone-positive, HR+, News, postmenopausal, Stage I Node Negative Breast Cancer, survival


October 28th, 2015

The Type of Breast Cancer Determines Effectiveness of Different Hormonal Therapies

By

According to the results of a recent study published in the Journal of Clinical Oncology, women with certain subtypes of hormone-positive breast cancer appear to benefit differently when treated with hormone therapy. Hormone-positive breast cancer refers to breast cancer that is stimulated to grow from the female hormone, estrogen. Therefore, a standard treatment component for […]

View full entry

Tags: AI, anti-estrogen agent, aromatase inhibitors, Breast Cancer, Femara, hormone-positive breast cancer, IDC, ILC, letrozole, News, tamoxifen